INDP vs NVO

Indaptus Therapeutics Inc.

Indaptus Therapeutics, Inc., a pre-clinical stage biotech company, develops a patented anti-cancer and antiviral immunotherapy. It engages in developing a pre-clinical pipeline of therapeutic candidates intended to elicit anti-tumor and anti-viral responses, as well as cure diseases. The company's lead candidate is Decoy20 that is in pre-clinical stage to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma. It also develops a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company is headquartered in New York, New York.

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.